241 related articles for article (PubMed ID: 36989735)
1. Development of certain aminoquinazoline scaffolds as potential multitarget anticancer agents with apoptotic and anti-proliferative effects: Design, synthesis and biological evaluation.
Amin NH; El-Saadi MT; Abdel-Fattah MM; Mohammed AA; Said EG
Bioorg Chem; 2023 Jun; 135():106496. PubMed ID: 36989735
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, modeling studies and biological evaluation of pyrazole derivatives linked to oxime and nitrate moieties as nitric oxide donor selective COX-2 and aromatase inhibitors with dual anti-inflammatory and anti-neoplastic activities.
A A Fadaly W; A M M Elshaier Y; T M Nemr M; R A Abdellatif K
Bioorg Chem; 2023 May; 134():106428. PubMed ID: 36893546
[TBL] [Abstract][Full Text] [Related]
3. Exploring new quinazolin-4(3H)-one derivatives as CDK2 inhibitors: Design, synthesis, and anticancer evaluation.
Ibrahim BT; Allam HA; El-Dydamony NM; Fouad MA; Mohammed ER
Drug Dev Res; 2024 Apr; 85(2):e22163. PubMed ID: 38419305
[TBL] [Abstract][Full Text] [Related]
4. Analysis of Quinolinequinone Analogs with Promising Cytotoxic Activity against Breast Cancer.
Yilmaz Goler AM; Tarbin Jannuzzi A; Biswas A; Mondal S; Basavanakatti VN; Jayaprakash Venkatesan R; Yıldırım H; Yıldız M; Çelik Onar H; Bayrak N; Jayaprakash V; TuYuN AF
Chem Biodivers; 2023 Sep; 20(9):e202300848. PubMed ID: 37590495
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of some new 6-bromo-2-(pyridin-3-yl)-4-substituted quinazolines as multi tyrosine kinase inhibitors.
Farouk AKBAW; Abdelrasheed Allam H; Rashwan E; George RF; Abbas SE
Bioorg Chem; 2022 Nov; 128():106099. PubMed ID: 35994884
[TBL] [Abstract][Full Text] [Related]
6. New Thiazolyl-Pyrazoline Derivatives as Potential Dual EGFR/HER2 Inhibitors: Design, Synthesis, Anticancer Activity Evaluation and In Silico Study.
Fakhry MM; Mattar AA; Alsulaimany M; Al-Olayan EM; Al-Rashood ST; Abdel-Aziz HA
Molecules; 2023 Nov; 28(21):. PubMed ID: 37959874
[No Abstract] [Full Text] [Related]
7. Novel Pyrazolo[3,4-d]pyrimidines as Potential Cytotoxic Agents: Design, Synthesis, Molecular Docking and CDK2 Inhibition.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
Anticancer Agents Med Chem; 2019; 19(11):1368-1381. PubMed ID: 31038080
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and evaluation of anti-proliferative activity of 2-aryl-4-aminoquinazoline derivatives as EGFR inhibitors.
Zhou Z; He J; Yang F; Pan Q; Yang Z; Zheng P; Xu S; Zhu W
Bioorg Chem; 2021 Jul; 112():104848. PubMed ID: 33819737
[TBL] [Abstract][Full Text] [Related]
9. Design, Synthesis and Antiproliferative Evaluation of Novel 1,2,4-Triazole/Schiff Base Hybrids with EGFR and B-RAF Inhibitory Activities.
El-Sherief HAM; Youssif BGM; Abdelazeem AH; Abdel-Aziz M; Abdel-Rahman HM
Anticancer Agents Med Chem; 2019; 19(5):697-706. PubMed ID: 30582484
[TBL] [Abstract][Full Text] [Related]
10. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
[TBL] [Abstract][Full Text] [Related]
11. Design and synthesis of novel pyrazolo[3,4-d]pyrimidin-4-one bearing quinoline scaffold as potent dual PDE5 inhibitors and apoptotic inducers for cancer therapy.
Ibrahim TS; Hawwas MM; Taher ES; Alhakamy NA; Alfaleh MA; Elagawany M; Elgendy B; Zayed GM; Mohamed MFA; Abdel-Samii ZK; Elshaier YAMM
Bioorg Chem; 2020 Dec; 105():104352. PubMed ID: 33080494
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, anticancer activity and effects on cell cycle profile and apoptosis of novel thieno[2,3-d]pyrimidine and thieno[3,2-e] triazolo[4,3-c]pyrimidine derivatives.
Kandeel MM; Refaat HM; Kassab AE; Shahin IG; Abdelghany TM
Eur J Med Chem; 2015 Jan; 90():620-32. PubMed ID: 25499930
[TBL] [Abstract][Full Text] [Related]
13. New thieno[3,2-d]pyrimidine-based derivatives: Design, synthesis and biological evaluation as antiproliferative agents, EGFR and ARO inhibitors inducing apoptosis in breast cancer cells.
Farghaly AM; AboulWafa OM; Baghdadi HH; Abd El Razik HA; Sedra SMY; Shamaa MM
Bioorg Chem; 2021 Oct; 115():105208. PubMed ID: 34365057
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and anticancer activity of novel 2-arylbenzimidazole/2-thiopyrimidines and 2-thioquinazolin-4(3H)-ones conjugates as targeted RAF and VEGFR-2 kinases inhibitors.
Ali IH; Abdel-Mohsen HT; Mounier MM; Abo-Elfadl MT; El Kerdawy AM; Ghannam IAY
Bioorg Chem; 2022 Sep; 126():105883. PubMed ID: 35636123
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and anticancer evaluation of new 4-anilinoquinoline-3-carbonitrile derivatives as dual EGFR/HER2 inhibitors and apoptosis inducers.
Zou M; Li J; Jin B; Wang M; Chen H; Zhang Z; Zhang C; Zhao Z; Zheng L
Bioorg Chem; 2021 Sep; 114():105200. PubMed ID: 34375195
[TBL] [Abstract][Full Text] [Related]
16. Synthesis, modification, and biological activity of propargylated methyl dihydroquinopimarates.
Tret'yakova EV; Salimova EV; Parfenova LV
Nat Prod Res; 2022 Jan; 36(1):79-86. PubMed ID: 32396399
[TBL] [Abstract][Full Text] [Related]
17. Novel benzotriazole N-acylarylhydrazone hybrids: Design, synthesis, anticancer activity, effects on cell cycle profile, caspase-3 mediated apoptosis and FAK inhibition.
Kassab AE; Hassan RA
Bioorg Chem; 2018 Oct; 80():531-544. PubMed ID: 30014921
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Evaluation of 2-Naphthaleno trans-Stilbenes and Cyanostilbenes as Anticancer Agents.
Madadi NR; Penthala NR; Ketkar A; Eoff RL; Trujullo-Alonso V; Guzman ML; Crooks PA
Anticancer Agents Med Chem; 2018; 18(4):556-564. PubMed ID: 28403783
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, molecular modelling and biological evaluation of novel 6-amino-5-cyano-2-thiopyrimidine derivatives as potent anticancer agents against leukemia and apoptotic inducers.
Ahmed NM; Mohamed MS; Awad SM; Abd El-Hameed RH; El-Tawab NAA; Gaballah MS; Said AM
J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2304625. PubMed ID: 38348824
[TBL] [Abstract][Full Text] [Related]
20. New Niflumic Acid Derivatives as EGFR Inhibitors: Design, Synthesis,
Yaseen YS; Mahmood AAR; Abbas AH; Shihab WA; Tahtamouni LH
Med Chem; 2023; 19(5):445-459. PubMed ID: 36537605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
